Clearmind Medicine Regains Nasdaq Compliance, Meeting Minimum Bid Price Requirement

miércoles, 31 de diciembre de 2025, 9:11 am ET1 min de lectura
CMND--

Clearmind Medicine has regained compliance with Nasdaq's minimum bid price requirement after receiving a notification letter from Nasdaq. The company had previously announced non-compliance with the minimum bid price requirement on December 4, 2025, but regained compliance on December 30, 2025. Clearmind Medicine is a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios